AstraZeneca falls on the stock market after buying Alexion Pharma
AstraZeneca shares fell more than 5% on the London Stock Exchange at noon, although they have fallen 10%, after closing the largest purchase in its history, the acquisition of Alexion Pharma, specializing in rare diseases, for 39 billion dollars. The British pharmaceutical company also recorded losses in the pre-opening of the New York Stock Exchange where the American Depositary Receipts (ADR) of AstraZeneca fell more than 4%.
As Alexion Pharma is also publicly traded, AstraZeneca will compensate the shareholders of the newly acquired company in cash and shares, paying $60 in cash for each Alexion share. Through this agreement, Alexion shareholders will control 15% after the takeover.
AstraZeneca has accumulated a revaluation of more than 8% on the New York Stock Exchange since the beginning of the year 2020, while on the London Stock Exchange, its price has barely changed during the same period.
Source: Admiral Markets MetaTrader 5. AstraZeneca ADR CFD Weekly Chart. Data range: from August 16, 2015, to December 14, 2020. Prepared on December 14, 2020, at 12 noon CET. Keep in mind that past returns do not guarantee future returns.
Do you think AstraZeneca will break the triangle support? With Admiral Markets UK Ltd you can speculate on the movement of AstraZeneca share prices both up and down using Contracts for Difference, or CFDs. If you want to start now, you have two options: open a free demo account with virtual money or open a real trading account by clicking on the following banner:
INFORMATION ON ANALYTICAL MATERIALS:
The data provided provides additional information on all analyzes, estimates, forecasts, forecasts, market reviews, weekly outlooks or other evaluations or similar information (hereinafter "Analysis") published on the Admiral Markets website. Before making any investment decisions, pay close attention to the following:
1. This is a marketing communication. The content is posted for informational purposes only and should not be construed as investment advice or recommendation. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research, and is not subject to any prohibition on pre-dissemination of investment research.
2. Each investment decision is made by each client alone, while Admiral Markets UK Ltd (Admiral Markets) will not be liable for any loss or damage arising from such a decision, whether based on content or not.
3. In order to protect the interests of our clients and the objectivity of the Analysis, Admiral Markets has established relevant internal procedures for the prevention and management of conflicts of interest.
4. The analysis is prepared by an independent analyst, Carolina Caro, SEO implementer (hereinafter "Author") based on personal estimates.
5. While all reasonable efforts are made to ensure that all sources of content are reliable and that all information is presented, as much as possible, in an understandable, timely, accurate, and complete manner, Admiral Markets does not guarantee accuracy. or integrity of any information contained in the Analysis.
6. Any past performance or modelling of the financial instruments indicated in the content should not be construed as an express or implied promise, guarantee, or implication of Admiral Markets for any future performance. The value of the financial instrument may rise and fall, and the preservation of the asset's value is not guaranteed.
7. Leveraged products (including contracts for difference) are speculative in nature and may generate profit or loss. Before you start trading, make sure you fully understand the risks.